<DOC>
	<DOC>NCT01096667</DOC>
	<brief_summary>MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and hypertension. Participants in the study will receive 1 of 5 treatments for 1 month including 1 treatment with an approved drug - hydrochlorothiazide (HCTZ).</brief_summary>
	<brief_title>Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Patients with type 2 diabetes and hypertension Medically stable On at least 1 (and up to 2) oral diabetes drugs And up to 2 medicines for blood pressure control Patients with type 1 diabetes Heart attack Stroke Uncontrolled blood pressure Significant kidney disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>hypertension</keyword>
	<keyword>ambulatory blood pressure monitoring</keyword>
</DOC>